Avoid common mistakes on your manuscript.
Correction: Gastric Cancer (2023) 26:1063–1068 https://doi.org/10.1007/s10120-023-01419-9
The Nov, 2023 article by Kodera et al. entitled “Addition of docetaxel to S-1 results in significantly superior 5-year survival outcomes in Stage III gastric cancer: a final report of the JACCRO GC-07 study” (Gastric Cancer https://doi.org/10.1007/s10120-023-01419-9) was published online on August 7, 2023, with errors.
The first sentence of the second paragraph in the Results section read as: Among the 912 patients, 190 patients in the S-1 plus docetaxel group and 236 patients in the S-1 monotherapy group showed recurrence during the 5 years of follow up, with the death of 167 patients and 206 patients, respectively.
It should have read as: During the 5 years of follow up, 426 events had been observed; 190 events in the S-1 plus docetaxel group and 236 events in the S-1 monotherapy group.
This has been corrected as of May 22, 2024. The authors apologize for the errors.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Kodera, Y., Yoshida, K., Kochi, M. et al. Correction: Addition of docetaxel to S-1 results in significantly superior 5-year survival outcomes in Stage III gastric cancer: a final report of the JACCRO GC-07 study. Gastric Cancer (2024). https://doi.org/10.1007/s10120-024-01519-0
Published:
DOI: https://doi.org/10.1007/s10120-024-01519-0